What Regeneron actually looks for
Regeneron, headquartered in Tarrytown, New York, was founded by Leonard Schleifer and George Yancopoulos and has built its reputation on genetics-driven drug discovery, most visibly through the Regeneron Genetics Center, which analyzes large-scale genetic data to identify promising drug targets before committing to expensive clinical development. Its commercial products include Eylea for wet age-related macular degeneration, Dupixent (co-developed with Sanofi) for inflammatory and allergic conditions, and REGEN-COV, the monoclonal antibody cocktail that gained public attention during the COVID-19 pandemic. Because Regeneron leans so heavily on its own proprietary platforms, including VelocImmune for generating human antibodies in genetically engineered mice, interviewers in R&D roles expect real fluency in how target discovery translates into a clinical candidate, not just general biotech knowledge. The company has a reputation for being founder-led and scientifically rigorous, with Yancopoulos still deeply involved in R&D direction.
Common questions and how to answer them
How does Regeneron's genetics-first approach change how you'd prioritize a drug target? Explain how large-scale genetic data from the Regeneron Genetics Center can validate a target's biological relevance before expensive clinical trials begin, reducing downstream failure risk compared to more traditional discovery approaches. Walk me through your understanding of Eylea's competitive position in retinal disease treatment. Show awareness of the eye disease treatment landscape and how Regeneron has defended and extended Eylea's franchise as biosimilar competition has emerged. Tell me about a time you had to make a decision based on ambiguous or early-stage data. Regeneron's research culture involves real scientific uncertainty; use a specific example that shows disciplined reasoning rather than overconfidence. In every case, ground your answer in Regeneron's genetics-first discovery approach, since interviewers use this as a consistent lens for evaluating whether candidates understand what differentiates the company scientifically.
How to prepare
Understand the basics of Regeneron's VelocImmune and Regeneron Genetics Center platforms well enough to explain how they differentiate the company's discovery process from competitors, since this comes up directly in R&D interviews. Know Regeneron's major products, Eylea, Dupixent, and its COVID-era antibody work, and be ready to discuss how the company has managed both its owned and partnered assets. Because Regeneron is founder-led with Yancopoulos closely involved in science, expect interviews to probe genuine scientific reasoning rather than surface-level business talking points, especially at senior levels. Expect R&D interviews to include a data or research presentation where you defend your reasoning to a panel of scientists, since Regeneron's founder-led culture values rigorous scientific debate.